Prof Sinead Delany-Moretlwe is the Director of Research at Wits RHI. She is the principal investigator of a population-effectiveness study of one and two doses of human papillomavirus (HPV) vaccination in South Africa. In the past two years, she has leveraged her HIV prevention experience and worked on several COVID-19 prevention trials. She is the national principal investigator for the CROWN Coronation Phase III trial of the mumps, measles and rubella (MMR) vaccine for the prevention of symptomatic COVID-19. She has worked with an extensive network of local and international collaborators and has experience working in both the United States and African regulatory frameworks.
She has served on several data monitoring committees for large randomised controlled trials. She is a reviewer for the South African Medical Research Council, the National Research Foundation and the National Institutes of Health in the USA, and is a member of the South African National pre-exposure prophylaxis (PrEP) Technical Working Group. She serves as a technical advisor to the WHO on issues related to STIs, HIV prevention and vaccine development. Prof Delany-Moretlwe is a member of the WHO’s Product Development for Vaccines Advisory Committee, the WHO Working Group for Therapeutic HPV vaccines, and the WHO’s HIV, Hepatitis and STIs Scientific and Technical Advisory Committee. She is a member of the executive committee of the HIV Prevention Trials Network (HPTN) and serves on the organising committees of several international conferences.